Van Eck Associates Corp Vertex Pharmaceuticals Inc Transaction History

Van Eck Associates Corp

$64.4 Billion
Q1 2024

A detailed history of Van Eck Associates Corp transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Van Eck Associates Corp holds 151,898 shares of VRTX stock, worth $71.2 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

151,898

Previous 174,227 12.82%

Holding current value

$71.2 Million

Previous $70.9 Million 10.44%

% of portfolio

0.1%

Previous 0.13%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 30, 2024	SELL	$407.69 - $446.08 $9.1 Million - $9.96 Million	-22,329 Reduced 12.82%	151,898 $63.5 Million
Q4 2023 Feb 05, 2024	BUY	$343.0 - $410.68 $7.02 Million - $8.4 Million	20,466 Added 13.31%	174,227 $70.9 Million
Q3 2023 Nov 08, 2023	SELL	$338.18 - $362.46 $3.51 Million - $3.76 Million	-10,368 Reduced 6.32%	153,761 $53.5 Million
Q2 2023 Aug 03, 2023	SELL	$314.42 - $351.91 $3.63 Million - $4.06 Million	-11,535 Reduced 6.57%	164,129 $57.8 Million
Q1 2023 May 03, 2023	BUY	$283.23 - $323.1 $3.4 Million - $3.88 Million	12,001 Added 7.33%	175,664 $55.3 Million

Q4 2022 Feb 08, 2023	SELL	$285.76 - $321.48 $3.29 Million - $3.7 Million	-11,507 Reduced 6.57%	163,663 $47.3 Million
Q3 2022 Oct 27, 2022	BUY	$273.83 - $305.53 $3.9 Million - $4.35 Million	14,239 Added 8.85%	175,170 $50.7 Million
Q2 2022 Aug 03, 2022	BUY	$234.96 - $292.55 $3.81 Million - $4.74 Million	16,201 Added 11.19%	160,931 $45.3 Million
Q1 2022 May 10, 2022	SELL	$221.42 - $260.97 $3.28 Million - $3.86 Million	-14,792 Reduced 9.27%	144,730 $37.8 Million
Q4 2021 Jan 26, 2022	SELL	$177.01 - $223.45 $3.48 Million - $4.39 Million	-19,656 Reduced 10.97%	159,522 $35 Million
Q3 2021 Nov 03, 2021	BUY	$181.39 - $202.99 $6.87 Million - $7.69 Million	37,885 Added 26.81%	179,178 $32.5 Million
Q2 2021 Aug 10, 2021	BUY	$187.49 - $221.1 $3.83 Million - $4.51 Million	20,403 Added 16.88%	141,293 $28.5 Million
Q1 2021 May 13, 2021	BUY	$207.02 - $241.31 $1.83 Million - $2.13 Million	8,816 Added 7.87%	120,890 $26 Million
Q4 2020 Feb 09, 2021	BUY	$207.01 - $276.09 $2.47 Million - $3.3 Million	11,937 Added 11.92%	112,074 $26.5 Million
Q3 2020 Nov 12, 2020	SELL	$255.65 - $303.1 $1.39 Million - $1.65 Million	-5,440 Reduced 5.15%	100,137 $27.2 Million
Q2 2020 Aug 10, 2020	BUY	$225.48 - $295.8 $6.95 Million - $9.12 Million	30,833 Added 41.25%	105,577 $30.7 Million
Q1 2020 May 12, 2020	SELL	$199.77 - $247.81 $3.06 Million - $3.8 Million	-15,326 Reduced 17.02%	74,744 $17.8 Million
Q4 2019 Feb 13, 2020	SELL	$166.71 - $223.91 $2.34 Million - $3.14 Million	-14,013 Reduced 13.46%	90,070 $19.7 Million
Q3 2019 Nov 08, 2019	SELL	$166.23 - $187.09 $1.12 Million - $1.26 Million	-6,728 Reduced 6.07%	104,083 $17.6 Million
Q2 2019 Aug 07, 2019	SELL	$164.61 - $190.37 $924,614 - $1.07 Million	-5,617 Reduced 4.82%	110,811 $20.3 Million
Q1 2019 May 13, 2019	BUY	$163.73 - $194.7 $192,219 - $228,577	1,174 Added 1.02%	116,428 $21.4 Million
Q4 2018 Feb 12, 2019	SELL	$151.91 - $192.21 $2.13 Million - $2.7 Million	-14,048 Reduced 10.86%	115,254 $19.1 Million
Q3 2018 Nov 13, 2018	SELL	$167.73 - $192.74 $1.78 Million - $2.04 Million	-10,602 Reduced 7.58%	129,302 $24.9 Million
Q2 2018 Aug 13, 2018	BUY	$145.72 - $169.96 $990,750 - $1.16 Million	6,799 Added 5.11%	139,904 $23.8 Million
Q1 2018 May 11, 2018	SELL	$151.6 - $177.13 $8.62 Million - $10.1 Million	-56,839 Reduced 29.92%	133,105 $21.7 Million
Q4 2017 Feb 12, 2018	SELL	$137.28 - $155.55 $2.39 Million - $2.7 Million	-17,388 Reduced 8.39%	189,944 $28.5 Million
Q3 2017 Nov 09, 2017	SELL	$148.13 - $162.24 $3.68 Million - $4.03 Million	-24,813 Reduced 10.69%	207,332 $31.5 Million
Q2 2017 Aug 11, 2017	BUY	N/A	232,145	232,145 $29.9 Million

Others Institutions Holding VRTX

# of Institutions

1,623

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $120B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

News

Stay updated on Van Eck Associates Corp with notifications on news.

Account

Van Eck Associates Corp Vertex Pharmaceuticals Inc Transaction History